Milan, Italy (Press Release) – MolMed S.p.A. (MLM.MI) and Genenta Science (Genenta) signed an agree­ment on a multi-year cooperation to develop and manu­fac­ture a gene ther­apy prod­uct for the treat­ment of multiple myeloma.

In accordance to this agree­ment, MolMed will develop and val­i­date the manu­fac­tur­ing and analytical methods of the Genenta prod­uct that constitute part of the preparatory activities to enter in the clin­i­cal trials. Further­more, MolMed will sup­port Genenta to file the appli­ca­tion dossier required for the authori­sa­tion to proceed with trials.

The agree­ment extends the col­lab­o­ration by ensuring MolMed exclusive …

Janssen and Genentech will enter clin­i­cal col­lab­o­ra­tion to assess dual mono­clonal anti­body (mAb) combi­na­tion ther­apy

Raritan, NJ (Press Release) – Janssen Research & Development, LLC announced today it has entered into a clin­i­cal trial col­lab­o­ra­tion agree­ment with Genentech, a member of the Roche Group, to ini­ti­ate two studies to de­ter­mine the safety and tolerability of dara­tu­mu­mab (DARZALEX®), the first CD38-directed mono­clonal anti­body (mAb), in combi­na­tion with atezo­lizu­mab, an investi­ga­tional mAb designed to bind with a protein called pro­grammed cell death-ligand 1 (PD-L1). These studies will assess the poten­tial of the combi­na­tion ther­apy in multiple myeloma and in solid tumor. Atezolizumab is cur­rently in devel­op­ment by Roche. Janssen …

• Phase Ib studies of dara­tu­mu­mab in com­bi­na­tion with Roche’s immune checkpoint inhibitor atezo­lizu­mab in a solid tumor and multiple myeloma to be started
• Studies conducted under a clin­i­cal trial col­lab­o­ra­tion agree­ment be­tween Janssen and Roche

Copenhagen, Denmark (Press Release) – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that dara­tu­mu­mab will be in­ves­ti­gated in early stage clin­i­cal studies in com­bi­na­tion with atezo­lizu­mab (anti-PD-L1 anti­body), in a solid tumor and multiple myeloma. The studies will be conducted under a clin­i­cal trial col­lab­o­ra­tion agree­ment be­tween Genmab’s licensing partner for dara­tu­mu­mab, Janssen Biotech, Inc., and Genentech, a member of the Roche Group. Atezolizumab is an inves­ti­ga­tional mono­clonal anti­body de­signed to bind to a protein called PD-L1, which is ex­pressed on tumor cells and …

• Combined entity aims to be a leader in oncolytic virotherapy discovery, devel­op­ment, and commer­cial­iza­tion
• Pipeline of immuno-oncology prod­ucts targets a broad range of cancers

Rochester, MN (Press Release) – Omnis Pharma, Inc. and Magnis Therapeutics, LLC, announced today their strategic merger to form Vyriad, a clin­i­cal-stage oncolytic immunovirotherapy devel­op­ment com­pany. The com­bined com­pa­nies' prod­uct devel­op­ment pipe­line encompasses multiple clin­i­cal-stage and late pre­clin­i­cal-stage prod­ucts targeting a broad range of human cancer indi­ca­tions, in­­clud­ing a Phase 1 de­vel­opment pro­gram partnered with a large pharma­ceu­tical com­pany. Financial …

• EVOMELA Received FDA Approval for Two Indications:
• High-Dose Conditioning Treatment for Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT)
• Palliative Treatment of Patients with MM Who Cannot Take Oral Therapy
• EVOMELA Admixture Solution is Stable for 4 Hours at Room Temperature in Addition to the 1 Hour Following Reconstitution
• EVOMELA Does Not Contain Propylene Glycol
• Company Plans to Launch EVOMELA with Existing Sales Force in a Market

 …

Philadelphia, PA (Press Release) – In almost every mammalian cell, you will find the endo­plasmic reticulum, a network of continuous membranes responsible for controlling metabolism as well as the folding, assembly and secretion of proteins. Since the endo­plasmic reticulum is critical in manu­fac­tur­ing important proteins that facilitate communication between cells, researchers are exploring new ways to find important targets within these membranes that could help stimulate immune responses against cancer cells.

Now, new research from The Wistar Institute shows how one protein found on the endo­plasmic reticulum can serve as a target …

Hoersholm, Denmark (Press Release) – Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) today announced that the first patient has been in­cluded in the APO010 Screening Protocol for Multiple Myeloma by MPI's spinout OV. This patient has entered the study at the first out of four planned participating Danish hematology sites. Approximately 150 patients will be screened using MPI's DRP(TM) (Drug Response Predictor), out-licensed to Oncology Venture. The DRP(TM) uses genomic in­­for­ma­tion from the individual cancer patient's tumor. The screen­ing will identify 15 patients with the highest likelihood to benefit …